Sunitinib, approved by FDA for the first line treatment of metastatic ccRCC in 2006, is such an inhibitor that targets the vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), Fms-like tyrosine kinase 3 (FLT3), colony stimulating factor-1 receptor (CSF1R), and tyrosine-protein kinase receptor RET [6]. This evidence concerns the gene CSF1R and nonpapillary renal cell carcinoma.